Peptide therapy on TikTok: separating hype from actual data

What did @kjsgoddard actually say?

The creator drew a direct comparison between peptides and anabolic steroids, arguing that steroids are "much more powerful" because they "stimulate a hormonal pathway," while peptides are generally designed to "decrease inflammation and promote a healing effect." The punchline: peptides carry a "much, much greater" safety profile than steroids. They also acknowledged the peptide category is broad, saying "you can go on for days of the reading about them."

To be fair, they didn't make wild therapeutic claims. They kept it general, flagged complexity, and didn't recommend any specific peptide or dose. That restraint is worth noting, because most peptide content on TikTok does none of those things.

Does the science back this up?

Partly. The broad strokes are defensible, but the blanket safety claim deserves real scrutiny. Anabolic-androgenic steroids (AAS) have a well-documented risk profile including hypogonadism, hepatotoxicity, dyslipidemia, and cardiovascular damage. Peptides, as a class, generally don't carry those same hormonal risks. But "generally" is doing a lot of heavy lifting here.

The problem is that "peptides" is not one thing. BPC-157 has shown anti-inflammatory and tissue-remodeling effects in rodent models (Seiwerth et al., 2018, Current Pharmaceutical Design), but there are no completed Phase III human trials. Growth hormone secretagogues like ipamorelin and CJC-1295 work precisely by stimulating a hormonal pathway, specifically the growth hormone axis, which is something the creator said peptides don't do. MK-677, often lumped into the peptide category despite being a non-peptide GHS, has raised concerns about insulin resistance and cortisol elevation (Copinschi et al., 1997, Sleep). The safety profile across this category is not uniform, and presenting it as such flattens important distinctions.

What did they get wrong (or right)?

They got the core steroids comparison roughly right. AAS directly bind androgen receptors systemically, producing potent anabolic and virilizing effects with significant suppression of the hypothalamic-pituitary-gonadal axis. Peptides, in most cases, work through more targeted signaling mechanisms and don't produce that level of hormonal disruption. Credit where it's due.

Where the creator stumbles is the phrase "nothing that is so strong as to stimulate what the steroids stimulate." Growth hormone-releasing peptides and their analogues literally stimulate the pituitary to release growth hormone. That is a hormonal pathway. It's a different pathway than androgen receptors, yes, and the effects are less dramatic in magnitude, but calling it non-hormonal is inaccurate. A viewer walking away from this video might think every peptide is essentially a mild anti-inflammatory supplement, and that's a misleading picture. GHS peptides require clinical oversight for the same reason GH therapy does: they influence IGF-1 levels, glucose metabolism, and potentially tumor growth in at-risk individuals (Liu et al., 2007, Annals of Internal Medicine).

The safety claim also lacks a caveat that matters: most peptide research is preclinical. Saying the safety profile is "much, much greater" implies that profile has been rigorously studied in humans. For most peptides in this category, it hasn't been. We don't know what we don't know yet.

What should you actually know?

The peptide-versus-steroid comparison is real but incomplete. Anabolic steroids have decades of human data showing serious harm at performance-enhancing doses. Most therapeutic peptides have far less human safety data, which cuts both ways: fewer confirmed harms, but also fewer confirmed long-term safety benchmarks.

Some peptides in this space, particularly growth hormone secretagogues, do influence hormonal systems and should not be treated as consequence-free. Anyone considering peptide therapy should do so through a regulated clinical setting where baseline labs, ongoing monitoring, and informed consent are part of the process. That's not a bureaucratic formality, it's how you catch problems before they compound.

The creator's instinct to flag complexity was correct. Peptides are not a monolith. BPC-157, TB-500, GHK-Cu, and ipamorelin have different mechanisms, different evidence bases, and different risk profiles. A comparison that collapses all of them into "safer than steroids" gives listeners a shortcut that may not serve them well when making actual health decisions.

Bottom line

This video is more responsible than most peptide content online, but its central safety claim oversimplifies a genuinely complex picture. The steroids comparison is broadly fair. The characterization of peptides as non-hormonal and uniformly low-risk is not. Approach both with the same thing: a clinician who has read the actual literature.